Fu-Dong Shi received his MD from Harbin Medical University and Peking Union Hospital in China. After completion of a five-year residency in Internal Medicine and Neurology in China, he was selected to receive research training at the Karolinska Institute, Stockholm, Sweden, where he obtained a PhD in Neurology. He completed postdoctoral research in the field of autoimmunity at The Scripps Research Institute, La Jolla, California. In 2004, he joined the faculty of the Division of Neurology at the Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center.
At Barrow, Dr. Fu-Dong Shi completed the United States Medical License Examination, obtained certification from the Educational Commission for Foreign Medical Graduates, and was matched to the Neurology residency at Barrow. He completes annual rotations in the Departments of Neurology and Child Neurology, with emphasis on the Neuroimmunology and Neuromuscular clinics. While running a highly dynamic laboratory program, Dr. Shi maintains his role as a research neurologist for clinical trials of new immunomodulatory compounds in patients with multiple sclerosis and myasthenia gravis.
Dr. Shi manages research programs funded by the National Institutes of Health (NIH) to dissect the role of innate immunity and inflammation in neurological disorders and to identify organ-specific features of natural killer cells in inflammation and tumorigenesis. He also administers long-term programs funded by the Muscular Dystrophy Association (MDA) to study the cellular mechanisms underlying the initiation and progression of autoantibody production by B cells in myasthenia gravis.
Dr. Shi’s work has been published in Nature Immunology, Nature Review Immunology, Proceedings of the National Academy of Sciences USA, Journal of Experimental Medicine, and Annals of Neurology, among other prestigious journals. Dr. Shi serves on Grant Review Panels for the Juvenile Diabetes Research Foundation (JDRF) and NIH. Dr. Shi also reviews articles for journals such as Journal of Immunology, Journal of Clinical Investigation, Journal of Experimental Medicine, Nature Immunology, Nature Medicine,Annals of Neurology, Lancet, and New England Journal of Medicine.
An avid outdoorsman, Dr. Shi enjoys hiking, tennis, swimming and gardening.
- Postdoctoral Fellowship, the Scripps Research Institute, Autoimmunity, 1995-1999
- PhD, Karolinska Institute, Experimental Neurology, 1999
- Residency, Harbin Medical University, Neurology, 1989-1995
- MD, Harbin Medical College and Peking Union Hospital, China, 1989
- American Association of Immunology
- American Neurological Association
- Changjiang Scholar Award Program, Ministry of Education, China
- Career Development Award, the Muscular Dystrophy Association
- Postdoctoral Fellowship Award, Juvenile Diabetes Foundation International
- Liu Q, Sanai N, Jin WN, La Cava A, Van Kaer L, Shi FD. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci. Feb 2016;19(2):243-252.
- Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, Dong Y, Xu X, Liu Q, Huang D, Shi FD. Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial. Circulation. Sep 22 2015;132(12):1104-1112.
- Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, Wang Y, Chen J, La Cava A, Poursine-Laurent J, Yokoyama W, Shi FD. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A. Feb 18 2014;111(7):2704-2709.
- Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, Han W, Xue R, Liu Q, Hao J, Yu C, Shi FD. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. Dec 23 2014;111(51):18315-18320.
- Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, Yan Y, Huang D, Yu C, Shi FD. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. Sep 2014;71(9):1092-1101.
- Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhangning N, Liu Q, Shao ZH, Yu C, Shi FD. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. Aug 20 2013;81(8):710-713.
- Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer L, La Cava A, Shi FD. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol. Apr 2011;69(4):721-734.
- Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van Kaer L, Shi FD. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med. Aug 30 2010;207(9):1907-1921.
- Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL, Wilson SB, Sarvetnick N. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A. Jun 5 2001;98(12):6777-6782.
- Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol. Sep 2000;1(3):245-251.